CGTX Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

$11.90
As of 10/15/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  10/08/2021
Outstanding shares:  20,953,196
Average volume:  628,955
Market cap:   $253,743,204
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    
ISIN:        
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   -2.98
PS ratio:   0.00
Return on equity:   1.51%
Net income %:   0.00%